Compare XRAY & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRAY | MESO |
|---|---|---|
| Founded | 1899 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2008 | N/A |
| Metric | XRAY | MESO |
|---|---|---|
| Price | $11.70 | $15.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $14.58 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 208.0K |
| Earning Date | 05-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 33.04 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $629.74 |
| Revenue Next Year | $2.06 | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $9.88 |
| 52 Week High | $17.18 | $21.50 |
| Indicator | XRAY | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 48.19 |
| Support Level | $10.96 | $14.44 |
| Resistance Level | $12.28 | $16.49 |
| Average True Range (ATR) | 0.44 | 0.43 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 13.91 | 39.08 |
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.